UBS Group’s Onconova Therapeutics, Inc. Warrants ONTXW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-13,171
| Closed | -$2K | – | 10768 |
|
|
2021
Q2 | $2K | Sell |
13,171
-23,113
| -64% | -$4.77K | ﹤0.01% | 9101 |
|
|
2021
Q1 | $11K | Buy |
36,284
+11,427
| +46% | +$3.43K | ﹤0.01% | 7895 |
|
|
2020
Q4 | $3K | Buy |
24,857
+21,073
| +557% | +$1.3K | ﹤0.01% | 8059 |
|
|
2020
Q3 | $0 | Hold |
3,784
| – | – | ﹤0.01% | 8673 |
|
|
2020
Q2 | $0 | Hold |
3,784
| – | – | ﹤0.01% | 8579 |
|
|
2020
Q1 | $0 | Sell |
3,784
-32,632
| -90% | -$4.06K | ﹤0.01% | 8652 |
|
|
2019
Q4 | $1K | Buy |
36,416
+32,632
| +862% | +$764 | ﹤0.01% | 8032 |
|
|
2019
Q3 | $0 | Hold |
3,784
| – | – | ﹤0.01% | 8421 |
|
|
2019
Q2 | $1K | Hold |
3,784
| – | – | ﹤0.01% | 7774 |
|
|
2019
Q1 | $0 | Buy |
3,784
+192
| +5% | +$24 | ﹤0.01% | 8391 |
|
|
2018
Q4 | $0 | Hold |
3,592
| – | – | ﹤0.01% | 8459 |
|
|
2018
Q3 | $0 | Sell |
3,592
-1,125
| -24% | -$180 | ﹤0.01% | 8412 |
|
|
2018
Q2 | $0 | Buy |
4,717
+1,125
| +31% | +$280 | ﹤0.01% | 8381 |
|
|
2018
Q1 | $1K | Buy |
3,592
+3,000
| +507% | +$1.12K | ﹤0.01% | 7694 |
|
|
2017
Q4 | $0 | Buy |
+592
| New | +$350 | ﹤0.01% | 8221 |
|
|
2017
Q3 | – | Sell |
-1,491
| Closed | -$1K | – | 8125 |
|
|
2017
Q2 | $1K | Hold |
1,491
| – | – | ﹤0.01% | 7550 |
|
|
2017
Q1 | $1K | Buy |
+1,491
| New | +$1.07K | ﹤0.01% | 7498 |
|
UBS Group's ONTXW Position: Q3 2021 in Review
UBS Group sold out of Onconova Therapeutics, Inc. Warrants (ONTXW) in Q3 2021, closing a stake of 13,171 shares — an estimated $2K sold.
UBS Group first reported a position in ONTXW in Q1 2017 and held it in 17 quarters. The position peaked at $11K in Q1 2021. 0 funds tracked by Wall St. Rank hold ONTXW as of Q3 2021.
- UBS Group reported no remaining Onconova Therapeutics, Inc. Warrants position as of Q3 2021 after selling out during the quarter.
- UBS Group sold 13,171 Onconova Therapeutics, Inc. Warrants shares in Q3 2021, an estimated $2K.
- UBS Group first reported a position in Onconova Therapeutics, Inc. Warrants in Q1 2017 and held it in 17 quarters.
- UBS Group's Onconova Therapeutics, Inc. Warrants position peaked at $11K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Onconova Therapeutics, Inc. Warrants as of Q3 2021.
Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.